Eligo Bioscience secures $30m in series B funding, advancing its innovative gene-editing solutions targeting diseases linked to bacterial genes within the human microbiome.
https://european-biotechnology.com/wp-content/uploads/2024/04/RS1684_AdobeStock_39048791-scaled.jpeg17072560Margarita Milidakis/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMargarita Milidakis2023-12-05 11:13:082024-07-09 12:58:33$30m for genetic medicine advancements